Published in Orphanet J Rare Dis on September 04, 2007
The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med (2013) 1.31
The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer (2008) 1.25
The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation. Front Immunol (2014) 0.86
Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. Exp Biol Med (Maywood) (2014) 0.86
Fulminant gastrointestinal graft-versus-host disease concomitant with cytomegalovirus infection: case report and literature review. World J Gastroenterol (2013) 0.80
Modulation of Immunoregulatory Properties of Mesenchymal Stromal Cells by Toll-Like Receptors: Potential Applications on GVHD. Stem Cells Int (2016) 0.80
Graft versus host disease: New insights into A2A receptor agonist therapy. Comput Struct Biotechnol J (2014) 0.79
Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. Proc Natl Acad Sci U S A (2015) 0.79
The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant (2015) 0.78
Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood (2016) 0.78
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.78
An epidermotypic model of interface dermatitis reveals individual functions of fas ligand and gamma interferon in hypergranulosis, cytoid body formation, and gene expression. Am J Dermatopathol (2011) 0.77
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia (2016) 0.76
Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. Clin Pharmacokinet (2016) 0.75
Antibody- and aptamer-strategies for GvHD prevention. J Cell Mol Med (2014) 0.75
Transforming growth factor-β1 polymorphisms and graft-versus-host disease risk: a meta-analysis. Oncotarget (2016) 0.75
Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications. J Clin Med (2015) 0.75
Oral manifestations in the Graft versus Host Disease in paediatric patients: case report. Oral Implantol (Rome) (2010) 0.75
Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. Braz J Med Biol Res (2017) 0.75
The Royan Public Umbilical Cord Blood Bank: Does It Cover All Ethnic Groups in Iran Based on HLA Diversity? Transfus Med Hemother (2014) 0.75
Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review. An Bras Dermatol (2016) 0.75
Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. Curr Oncol (2017) 0.75
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. Front Pharmacol (2017) 0.75
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant (2002) 3.29
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol (2001) 2.69
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
How I treat chronic graft-versus-host disease. Blood (2001) 2.20
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09
How I treat refractory acute GVHD. Blood (2007) 2.05
Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 1.90
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (1999) 1.58
The pathophysiology of acute graft-versus-host disease. Int J Hematol (2003) 1.55
Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am J Surg Pathol (1979) 1.55
Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood (2002) 1.47
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood (2001) 1.46
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood (2002) 1.46
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood (2004) 1.42
Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation (2001) 1.41
Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis (2001) 1.34
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant (2004) 1.33
Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation (1991) 1.30
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica (2006) 1.27
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant (2002) 1.27
Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation (1993) 1.18
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood (2005) 1.18
Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. Br J Haematol (1990) 1.17
Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol (2005) 1.15
Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood (2007) 1.10
Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood (2002) 1.10
Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med (1990) 1.07
Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood (2003) 1.05
Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood (1990) 0.99
Review article: management of hepatic disease following haematopoietic cell transplant. Aliment Pharmacol Ther (2006) 0.99
Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol (2007) 0.97
Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant (2004) 0.97
A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant (2004) 0.94
High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut (1983) 0.93
Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients. J Infect (2005) 0.91
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood (1988) 0.90
A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant (1997) 0.90
Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol (2004) 0.89
Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy. Pediatrics (2004) 0.86
High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation (1984) 0.84
Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia. Bone Marrow Transplant (2004) 0.83
Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol (2006) 0.81
Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J Immunol (2001) 0.80
Skin biopsy in allogeneic and autologous bone marrow transplant patients: a histologic and immunohistochemical study and review of the literature. Mod Pathol (1995) 0.79
Hepatitic pattern of graft versus host disease in children. Pediatr Blood Cancer (2007) 0.77
Graft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: correlations with marrow hematopoietic and lymphoid subsets. Prog Clin Biol Res (1994) 0.76
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant (2010) 1.69
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant (2011) 1.54
Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology (2011) 1.50
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant (2010) 1.34
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 1.33
Chronic graft versus host disease. Br J Haematol (2004) 1.33
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood (2003) 1.29
Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol (2007) 1.27
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant (2002) 1.27
Stem cell transplantation: supportive care and long-term complications. Hematology Am Soc Hematol Educ Program (2002) 1.24
Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol (2005) 1.15
Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 1.10
Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood (2002) 1.10
Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol (2003) 1.06
Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol (2014) 1.04
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant (2006) 0.99
Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant (2003) 0.97
Myxedema ascites in the posttransplant setting: case report. Am J Hematol (2002) 0.94
Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol (2005) 0.93
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant (2008) 0.89
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant (2003) 0.89
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant (2007) 0.88
A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res (2002) 0.87
Acute graft-versus-host disease. Clin Adv Hematol Oncol (2004) 0.86
Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant (2005) 0.85
Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des (2004) 0.84
Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood (2009) 0.83
The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant (2005) 0.83
Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L. Transfusion (2007) 0.83
Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L. Transfusion (2007) 0.82
Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev (2004) 0.80
Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. Am J Hematol (2005) 0.80
Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother (2004) 0.79
Grover's Disease after Bone Marrow Transplantation. Biol Blood Marrow Transplant (2007) 0.79
Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs (2002) 0.79
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. Br J Haematol (2002) 0.79
Hepatic venoocclusive disease in blood and bone marrow transplantation in children: incidence, risk factors, and outcome. J Pediatr Hematol Oncol (2002) 0.78
Chronic graft-versus-host disease. Curr Pharm Des (2008) 0.78
Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol (2003) 0.78
Mesenchymal stem cells and organ transplantation: current status and promising future. Transplantation (2006) 0.77
Rapid engraftment at a cost? Transplantation (2010) 0.75
Montelukast in chronic graft-versus-host disease: a breath of fresh air? Transplantation (2007) 0.75
Keeping up with Blood: introducing our CME program. Blood (2010) 0.75